Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors

  • Immutep Limited IMMP has announced a new collaboration and supply agreement with Germany-based Merck KGaA MKGAF for a Phase 1/2a INSIGHT-005 trial in patients with solid tumors.
  • The trial will evaluate the feasibility, safety, and efficacy of Immutep’s lead product candidate, eftilagimod alpha (efti or IMP321), in combination with bintrafusp alfa (M7824).
  • Bintrafusp alfa is an investigational bifunctional fusion protein immunotherapy jointly developed by Merck Germany and GlaxoSmithKline Plc GSK.
  • Bintrafusp alfa aims to block two immunosuppressive pathways, TGF-β and PD-L1, while efti activates antigen-presenting cells via the LAG-3 – MHC II pathway.
  • The first patient will be enrolled in mid-2021, with the first data expected in early 2022.
  • Price Action: IMMP shares are up 7.3% at $5.4 during the premarket session on the last check Tuesday.
Posted In: BriefsSolid TumorBiotechNewsHealth CareSmall CapFDAGeneral